|Bid||60.42 x 1400|
|Ask||62.40 x 1800|
|Day's range||61.79 - 62.35|
|52-week range||46.48 - 62.35|
|Beta (5Y monthly)||0.18|
|PE ratio (TTM)||43.37|
|Forward dividend & yield||1.40 (2.27%)|
|Ex-dividend date||12 Aug 2021|
|1y target est||69.28|
WILMINGTON, Del., October 25, 2021--Positive high-level results from the TOPAZ-1 Phase III trial showed IMFINZI® (durvalumab), in combination with standard-of-care chemotherapy, demonstrated a statistically significant and clinically meaningful overall survival (OS) benefit versus chemotherapy alone as a 1st-line treatment for patients with advanced biliary tract cancer (BTC).
AstraZeneca (NASDAQ: AZN) awaits U.S. Emergency Use Authorization for its COVID-19 antibody therapy as a prophylaxis. In this Motley Fool Live video recorded on Oct. 13, Motley Fool contributors Keith Speights and Brian Orelli discuss how effective AstraZeneca might be in competing against antibody therapies marketed by COVID-19 antibody therapies already on the market.
Former U.S. Commerce Sec. Gary Locke weighs in on the global vaccine equity debate and how the U.S. can better respond to the ongoing pandemic.